Final Report Summary - INNOVAHEALTH (Open Innovation For Health: A Strategy for 2020)
The INNOVAHEALTH project was established to provide and open innovation strategy for healthcare for Europe and inform Horizon 2020 in the area of health and wellness. The sustainability of European healthcare systems is under threat - the ageing of the European population, the prevalence of chronic disease and a need to focus on wellness and preventative health management, in parallel with treatment of disease, pose significant social and economic challenges. The current economic situation has made these issues more acute. In addition, many healthcare-related industries have reduced their research and development (R&D) bases in Europe and intellectual property generated within the European Union (EU) is frequently commercialised elsewhere.
Europe still has significant strengths in healthcare - a strong academic base and industrial leadership in areas such as pharmaceuticals, medical devices, mobile technologies and diagnostics as well as a strong public healthcare ethic. Initiatives in open innovation like the Innovative Medicines Initiative and the recently launched European Alliance for Personalised Medicine (EAPM), have shown that Europe can capture and capitalise on collaborations between industry, small amd medium-sized enterprises (SMEs), academia and other stakeholders in the healthcare system to create intellectual and economic impact. Europe is now uniquely placed to build on these competitive advantages to create an open Innovation ecosystem for healthcare, which would promote economic growth, increase employment, improve citizen centric health and wellness and reduce healthcare costs.
During the project a task force of key stakeholders was established including healthcare providers and patients as well as industry representatives. The aim was to create a strategy document that would provide a framework and recommendations for the creation of an open innovation ecosystem for healthcare in Europe. Several meetings in Brussels and many teleconferences were held which resulted in a draft strategy document which was submitted to the INNOVAHEALTH conference in Cyprus in October 2012. The report and then presented to both the ESPCO and Competitiveness Council meetings held in December 2012. It is anticipated that if the recommendations are taken up then Europe would be well placed to exploit new scientific and technological advances in healthcare with resulting impact on societal health and wellness and improved healthcare economics as well as creating new jobs in healthcare related R&D. The address of the project public website is http://www.innovahealth.ws
Project context and objectives:
The main deliverables of the project for this period were:
1. the establishment of a task force of experts to begin to work on the development of a strategy document;
2. development of a concise strategy document on open innovation in healthcare through establishment of a task force which met and talked at regular intervals;
3. the organisation of a conference on OI in the second part of 2012 when the Republic of Cyprus will hold the Presidency of the European Union (EU).
In order to achieve the above, meetings and telephone conferences were held between the partners and the task force thereafter to put together the main pillars of the strategy document and develop all the steps of the project. The conference was organised in October 2012 and was attended by 120 participants. We invited from each Member State two participants from the Ministry of Health and two from the ministries for research. The opening ceremony was also attended by the European Commissioners for Health and Research.
Work progress and achievements during the period
Work package (WP) 1:
OI Pharma Partners Ltd presented a plan outline and proposed the composition of a 'task force' of experts to develop this strategy document. These experts will be the key speakers to the OI in health conference and they agreed to develop a strategy document originally to be called 'Open innovation for health-A 2020 strategy'. The title was revised to 'Building an open innovation ecosystem in Europe for healthcare'. The task force and other contributors were:
Alastair Benbow - European Brain Council
Andriana Achilleos - Cyprus Ministry of Health
Annette Neath - NHS Institute for Innovation
David Phillips - SROne, GlaxoSmithKline
David Kerr - University of Oxford
Elisabeth Goodman - OI Pharma Partners Ltd
Emmanuel Chantelot - Shire
Hanno Cappon - Nutricia / Danone
Ian Walker - Caris Life Science
Jackie Hunter - OI Pharma Partners Ltd
Jacky Vonderscher - Roche
Jason Hannon - Roche
John Crawford - IBM Healthcare and Life Sciences
Lars Sundstrom- SATRE, Bristol and Cardiff Universities
Lisa Bonadonna - GlaxoSmithkline Vaccines
Lynne Maher - NHS Institute for Innovation
Marivi Mendizabel - GE Healthcare
Mark Effingham - IBM Healthcare and Life Sciences
Mary Baker - European Brain Council
Michel Goldman - IMI Executive Office
Mike Barnes - OI Pharma Partners Ltd
Rashik Parmar - IBM Healthcare and Life Sciences
Ray Pinto - Microsoft Health Care Technology and Industry Solutions
Stavros Malas - Minister, Cyprus Ministry of Health
WP 2:
The task force had two face-to-face meetings in Brussels. One occurred in August 2011 and the second in January 2012. In addition some members attended the 'Open innovation in health' meeting held in Brussels in March 2011. The outcome of these meetings and numerous email and telephone calls was the development of the Strategy document and the planning of the conference in Cyprus in October. This document had inputs from several people and by the end of the reporting period it was ready for submission to the OI conference.
WP 3:
Presidency conference, held in October 2012, to debate strategy document and deliver consensus view on implementation routes on OI in Health. The conference was organised over a three-day program. The Commissioners for Research and Health attended the official opening of the conference. The full program is appended as appendix listed below. The list of all attendees is appended as Appendix II. The conference was attended by policy-makers and senior officials from industry. On the morning before the opening ceremony, the Innovative Medicines Initiative (IMI; see http://www.imi.europa.eu/ for details) organised at the same place the Members States Representatives meeting so that these officials had the chance to attend the INNOVAHEALTH meeting as well. During the conference, all main pillars of the strategy document were presented and discussed by participants. A draft strategy was presented and debated. All participants commented on the uniqueness of this conference in bringing together officials from research organisation and a diverse spectrum of industry representatives. The final strategy document is presented as Appendix III.
WP 4:
The Strategy document was submitted to the Competitiveness Council in December 2012. In addition, the document was posted to the webpage of the project (see http://www.innovahealth.ws/ online), and was sent by electronic means to many research organisations, funding bodies and policy makers.
In addition In November 2012 a presentation was organised at the European Parliament where the report was presented by a senior IT officer of the Ministry of Health. The event was attended by several MEPs and a round table discussion followed.
Potential impact:
Impact
This project was very well received by the scientific community and policy makers as for the first time stakeholders across a wide spectrum of areas relating to Health came together and discussed issues relating to open Innovation in the Health area. In the light of a new urge by the European Commission (EC) for more open innovation activities, this project acted as a prototype platform to widen the discussion on this matter. The political leadership was also exposed to the project report through presenting the findings of the meeting and the summary of the strategy document to both the EPSCO and Competiveness Council meetings in December of 2012.
The project will have a significant impact in the way healthcare is integrated across Europe and provide a framework for non-traditional stakeholders eg mobile phone providers, who are already entering the healthcare space to engage with and be integrated into existing frameworks. Additionally, the creation of an open innovation strategy across these various sectors will allow the EU to capitalise on previous initiatives such as the IMI and ENIAC and to leverage them for the future benefit of EU citizens and services.
The development of OI strategy in healthcare policy document would provide a unique opportunity globally for the EU to capitalise on the willingness of various industrial sectors, academics, healthcare providers and other stakeholders to work together in different ways sharing more information and leverage their IP to create new solutions to healthcare challenges, IP, companies and jobs. This should:
- increase the attractiveness of Europe as a cross sector research and development (R&D) centre for healthcare applications,
- increase the ability of European citizens to have a consistent set of tools and information to allow them to own and manage their 'wellness' more effectively. This in turn will increase productivity and independence especially in the ageing population,
- the implementation of devices, strategies and tools prevent or monitor disease progression allowing more effective patient management and reducing the cost and time burdens on healthcare systems,
- accelerate the application of the outputs of the JTIs and other framework programmes e.g. integration of biomarkers into clinical practice for stratified medicine, novel utilisation of developments in three-dimensional (3D) imaging technology, incorporation or remote health monitoring systems into publically funded healthcare systems. This in turn would also have social benefits such as the reduction of hospital stay duration and costs;
- allow for the creation of a pan EU approach to stratified medicine and diagnostics that will increase the effectiveness of treatment, decrease incidence of adverse events and increase the percentage of phase II trials carried out in Europe.
An open innovation strategy would identify where the opportunities for industries and academics to work together would have the most impact on the European healthcare agenda and the bottlenecks that need to be addressed before this can happen. This would include identification of possibilities to reduce the bureaucratic burden of collaboration both within industries and across industries and academia and healthcare institutions. The involvement of regulators, consumers and other public bodies will also be important.
Project website:
http://www.innovahealth.ws
Europe still has significant strengths in healthcare - a strong academic base and industrial leadership in areas such as pharmaceuticals, medical devices, mobile technologies and diagnostics as well as a strong public healthcare ethic. Initiatives in open innovation like the Innovative Medicines Initiative and the recently launched European Alliance for Personalised Medicine (EAPM), have shown that Europe can capture and capitalise on collaborations between industry, small amd medium-sized enterprises (SMEs), academia and other stakeholders in the healthcare system to create intellectual and economic impact. Europe is now uniquely placed to build on these competitive advantages to create an open Innovation ecosystem for healthcare, which would promote economic growth, increase employment, improve citizen centric health and wellness and reduce healthcare costs.
During the project a task force of key stakeholders was established including healthcare providers and patients as well as industry representatives. The aim was to create a strategy document that would provide a framework and recommendations for the creation of an open innovation ecosystem for healthcare in Europe. Several meetings in Brussels and many teleconferences were held which resulted in a draft strategy document which was submitted to the INNOVAHEALTH conference in Cyprus in October 2012. The report and then presented to both the ESPCO and Competitiveness Council meetings held in December 2012. It is anticipated that if the recommendations are taken up then Europe would be well placed to exploit new scientific and technological advances in healthcare with resulting impact on societal health and wellness and improved healthcare economics as well as creating new jobs in healthcare related R&D. The address of the project public website is http://www.innovahealth.ws
Project context and objectives:
The main deliverables of the project for this period were:
1. the establishment of a task force of experts to begin to work on the development of a strategy document;
2. development of a concise strategy document on open innovation in healthcare through establishment of a task force which met and talked at regular intervals;
3. the organisation of a conference on OI in the second part of 2012 when the Republic of Cyprus will hold the Presidency of the European Union (EU).
In order to achieve the above, meetings and telephone conferences were held between the partners and the task force thereafter to put together the main pillars of the strategy document and develop all the steps of the project. The conference was organised in October 2012 and was attended by 120 participants. We invited from each Member State two participants from the Ministry of Health and two from the ministries for research. The opening ceremony was also attended by the European Commissioners for Health and Research.
Work progress and achievements during the period
Work package (WP) 1:
OI Pharma Partners Ltd presented a plan outline and proposed the composition of a 'task force' of experts to develop this strategy document. These experts will be the key speakers to the OI in health conference and they agreed to develop a strategy document originally to be called 'Open innovation for health-A 2020 strategy'. The title was revised to 'Building an open innovation ecosystem in Europe for healthcare'. The task force and other contributors were:
Alastair Benbow - European Brain Council
Andriana Achilleos - Cyprus Ministry of Health
Annette Neath - NHS Institute for Innovation
David Phillips - SROne, GlaxoSmithKline
David Kerr - University of Oxford
Elisabeth Goodman - OI Pharma Partners Ltd
Emmanuel Chantelot - Shire
Hanno Cappon - Nutricia / Danone
Ian Walker - Caris Life Science
Jackie Hunter - OI Pharma Partners Ltd
Jacky Vonderscher - Roche
Jason Hannon - Roche
John Crawford - IBM Healthcare and Life Sciences
Lars Sundstrom- SATRE, Bristol and Cardiff Universities
Lisa Bonadonna - GlaxoSmithkline Vaccines
Lynne Maher - NHS Institute for Innovation
Marivi Mendizabel - GE Healthcare
Mark Effingham - IBM Healthcare and Life Sciences
Mary Baker - European Brain Council
Michel Goldman - IMI Executive Office
Mike Barnes - OI Pharma Partners Ltd
Rashik Parmar - IBM Healthcare and Life Sciences
Ray Pinto - Microsoft Health Care Technology and Industry Solutions
Stavros Malas - Minister, Cyprus Ministry of Health
WP 2:
The task force had two face-to-face meetings in Brussels. One occurred in August 2011 and the second in January 2012. In addition some members attended the 'Open innovation in health' meeting held in Brussels in March 2011. The outcome of these meetings and numerous email and telephone calls was the development of the Strategy document and the planning of the conference in Cyprus in October. This document had inputs from several people and by the end of the reporting period it was ready for submission to the OI conference.
WP 3:
Presidency conference, held in October 2012, to debate strategy document and deliver consensus view on implementation routes on OI in Health. The conference was organised over a three-day program. The Commissioners for Research and Health attended the official opening of the conference. The full program is appended as appendix listed below. The list of all attendees is appended as Appendix II. The conference was attended by policy-makers and senior officials from industry. On the morning before the opening ceremony, the Innovative Medicines Initiative (IMI; see http://www.imi.europa.eu/ for details) organised at the same place the Members States Representatives meeting so that these officials had the chance to attend the INNOVAHEALTH meeting as well. During the conference, all main pillars of the strategy document were presented and discussed by participants. A draft strategy was presented and debated. All participants commented on the uniqueness of this conference in bringing together officials from research organisation and a diverse spectrum of industry representatives. The final strategy document is presented as Appendix III.
WP 4:
The Strategy document was submitted to the Competitiveness Council in December 2012. In addition, the document was posted to the webpage of the project (see http://www.innovahealth.ws/ online), and was sent by electronic means to many research organisations, funding bodies and policy makers.
In addition In November 2012 a presentation was organised at the European Parliament where the report was presented by a senior IT officer of the Ministry of Health. The event was attended by several MEPs and a round table discussion followed.
Potential impact:
Impact
This project was very well received by the scientific community and policy makers as for the first time stakeholders across a wide spectrum of areas relating to Health came together and discussed issues relating to open Innovation in the Health area. In the light of a new urge by the European Commission (EC) for more open innovation activities, this project acted as a prototype platform to widen the discussion on this matter. The political leadership was also exposed to the project report through presenting the findings of the meeting and the summary of the strategy document to both the EPSCO and Competiveness Council meetings in December of 2012.
The project will have a significant impact in the way healthcare is integrated across Europe and provide a framework for non-traditional stakeholders eg mobile phone providers, who are already entering the healthcare space to engage with and be integrated into existing frameworks. Additionally, the creation of an open innovation strategy across these various sectors will allow the EU to capitalise on previous initiatives such as the IMI and ENIAC and to leverage them for the future benefit of EU citizens and services.
The development of OI strategy in healthcare policy document would provide a unique opportunity globally for the EU to capitalise on the willingness of various industrial sectors, academics, healthcare providers and other stakeholders to work together in different ways sharing more information and leverage their IP to create new solutions to healthcare challenges, IP, companies and jobs. This should:
- increase the attractiveness of Europe as a cross sector research and development (R&D) centre for healthcare applications,
- increase the ability of European citizens to have a consistent set of tools and information to allow them to own and manage their 'wellness' more effectively. This in turn will increase productivity and independence especially in the ageing population,
- the implementation of devices, strategies and tools prevent or monitor disease progression allowing more effective patient management and reducing the cost and time burdens on healthcare systems,
- accelerate the application of the outputs of the JTIs and other framework programmes e.g. integration of biomarkers into clinical practice for stratified medicine, novel utilisation of developments in three-dimensional (3D) imaging technology, incorporation or remote health monitoring systems into publically funded healthcare systems. This in turn would also have social benefits such as the reduction of hospital stay duration and costs;
- allow for the creation of a pan EU approach to stratified medicine and diagnostics that will increase the effectiveness of treatment, decrease incidence of adverse events and increase the percentage of phase II trials carried out in Europe.
An open innovation strategy would identify where the opportunities for industries and academics to work together would have the most impact on the European healthcare agenda and the bottlenecks that need to be addressed before this can happen. This would include identification of possibilities to reduce the bureaucratic burden of collaboration both within industries and across industries and academia and healthcare institutions. The involvement of regulators, consumers and other public bodies will also be important.
Project website:
http://www.innovahealth.ws